Medically assisted reproductive (MAR) treatments using donated oocytes are commonly applied in several countries to treat women who cannot conceive with their own gametes. Historically, in Italy, gamete donation has been prohibited but, in 2014, the law changed and gamete donation became allowed for couples undergoing MAR treatments. Consequently, in the last decade, there has been an increase in application of the oocyte donation programme. This study reports an egg-donation programme's clinical efficacy, based on importing donated vitrified oocytes from cryo-banks located in a foreign country. For this, we conducted a retrospective analysis of data from a single reproductive unit located in Italy (Donna Salus Women's Health and Fertility, Bozen). The study group consisted of 681 vitrified oocytes, which were warmed and culture to be replaced in 100 recipients. The survival rate after warming was 79.1% (n = 539/681), whereas the fertilization and blastulation rates were 90.2% (n = 486/539) and 47.9% (n = 233/486), respectively. Positive pregnancy test, clinical pregnancy rates, and live-birth rates per embryo transfer were 37.8%, 31.1% and 28.4%, respectively. The multiple pregnancy rate was 0.7%. This study is one of the first to report on the efficacy of a donor oocyte programme in Italy using imported vitrified oocytes. The above data may reassure women who are undertaking donation programmes using vitrified oocytes imported from commercial egg banks.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1017/S0967199421000204 | DOI Listing |
J Assist Reprod Genet
January 2025
Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Purpose: This study is to evaluate duration of oocyte cryostorage and association with thaw survival, fertilization, blastulation, ploidy rates, and pregnancy outcomes in patients seeking fertility preservation.
Methods: Retrospective cohort study to evaluate clinical outcomes in patients who underwent fertility preservation from 2011 to 2023 via oocyte vitrification for non-oncologic indications. Primary outcome was thaw survival rate.
J Assist Reprod Genet
December 2024
Departament of Reproductive Medicine, Instituto Bernabeu, Alicante, Spain.
Purpose: To compare the efficacy of modified natural cycle (mNC) preparation versus hormone replacement therapy (HRT) for endometrial preparation in recipients of donated oocytes, specifically focusing on pregnancy rates in women of advanced maternal age.
Methods: Retrospective multicenter analysis conducted between 2021 and 2024. It includes 220 cycles of fresh single blastocyst transfers resulting from oocyte donation.
J Assist Reprod Genet
December 2024
State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, 250012, China.
Purpose: This study aims to explore the impact of a woman's previous cesarean delivery (CD) on pregnancy and neonatal outcomes for subsequent in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) and single frozen-thawed embryo transfer (FET), compared with vaginal delivery (VD).
Methods: This was a retrospective cohort study that included a total of 5817 patients who desired to transfer a single vitrified-thawed blastocyst from the same oocyte retrieval cycle as their last live birth between January 2011 and January 2021 at a single reproductive medicine center. Patients with a single previous CD were classified in the CD group, while those with a single VD were assigned to the VD group.
Fertil Steril
December 2024
Shady Grove Fertility, San Diego, California, USA.
Reprod Biomed Online
August 2024
Kuramoto Women's Clinic, Hakata-Ku, Fukuoka City, Japan.
Research Question: What are the clinical effects of using culture media supplemented with antioxidants (AOX) throughout the IVF process?
Design: Prospective randomized single-centre study. Cumulus-oocyte complexes and semen samples collected from 127 treatment cycles were divided evenly between the study arm (culture media with AOX) and the control arm (culture media without AOX). The primary endpoint was the good-quality blastocyst (GQB) rate on day 5-6 per metaphase II (MII) oocyte.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!